|Day Low/High||173.60 / 176.70|
|52 Wk Low/High||151.80 / 195.81|
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.
From Abbott Labs to Wynn, these names rate checking out.
It's a wonder to me how split this market really is.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an initiative that funds innovative, patient-centric programs for the CF...
Here are Tuesday's top research calls, including new coverage of Adobe and Okta, a downgrade for Advanced Micro Devices and an upgrade for Chegg.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIMC, CMRE, COG, CVX, HMC, KOF, MGM, MITK, MPLX, NTL, PSX, PXLW, TROW, VRTX Downgrades: AGCO, DRAD, DXR, HTBI, HUBG, IIJI, LII, ROIC, SKY, VSEC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2017.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close.
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
Investors ran for the exits after analysts pointed out that glowing Phase 2 study results for Corbus actually weren't that great. But a better story lies behind this biotech play.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
It's pretty normal to have profit-taking after such a strong first quarter.
Illumina, Centene, Community Health, Incyte and Vertex were among the healthcare stocks that did well in the first quarter.
Corbus Pharmaceuticals waves a sea of hands in front of investors' eyes Thursday to obscure dismal results from another mid-stage study of its experimental anti-inflammatory drug anabasum.
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.
Stocks are mixed on Wednesday as financials retreat again while tech names move higher.
Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.
Stock futures edge higher on Wednesday as markets await the United Kingdom taking the first step to formally remove itself from the European Union.
Here are Wednesday's top research calls, including a downgrade of Twitter and new coverage of Facebook, Amazon and Alphabet.
Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.